Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population

Nephrology Dialysis Transplantation

Volumn 29, Issue 6, 2014, Pages 1232-1238

  Rasch, Magnus G ^a,b   Helleberg, Marie ^a,b   Feldt Rasmussen, Bo ^b   Kronborg, Gitte ^c   Larsen, Carsten S ^d   Pedersen, Court ^e   Pedersen, Gitte ^f   Gerstoft, Jan ^a   Obel, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CKD; Dialysis; eGFR; ESRD; HIV; renal replacement therapy

Indexed keywords

ATAZANAVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENMARK; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR;

CKD; DIALYSIS; EGFR; ESRD; HIV; RENAL REPLACEMENT THERAPY;

ADENINE; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; COMORBIDITY; DENMARK; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PYRIDINES; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY; RISK FACTORS;

EID: 84901746106     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft289     Document Type: Article

References (30)

1. Crum N, Riffenburgh R, Wegner S et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194-200
2. Lohse N, Hansen A-B, Jensen-Fangel S et al. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis 2005; 37: 338-343 (Pubitemid 40691514)
3. Rasch MG, Engsig FN, Feldt-Rasmussen B et al. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis 2012; 44: 689-696
4. Choi A, Shlipak M, Hunt P et al. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009; 23: 2143-2149
5. Rodriguez-Nvoa S, Alvarez E, Labarga P et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Safety 2010; 9: 545-559
6. Eira M, Araujo M, Seguro AC. Urinary NO3 excretion and renal failure in indinavir-treated patients. Braz J Med Biol Res 2006; 39: 1065-1070
7. Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV type-1. Ann Intern Med 2011; 154: 445-456
8. Bruggeman LA, Ross MD, Tanji N et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11: 2079-2087
9. Marras D, Bruggeman LA, Gao F et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002; 8: 522-526 (Pubitemid 34546757)
10. Bickel M, Marben W, Betz C et al. End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. HIV Med 2013; 14: 127-135
11. Choi AI, Rodriguez RA, Bacchetti P et al. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 2007; 18: 2968-2974 (Pubitemid 350058405)
12. Ryom L, Kirk O, Lundgren J et al. Advanced renal disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. J Int AIDS Soc 2012; 15: 18136
13. Obel N, Engsig FN, Rasmussen LD et al. Cohort profile: the Danish HIV cohort study. Int J Epidemiol 2009; 38: 1202-1206
14. Heaf JG, Wehberg S. Reduced incidence of end stage renal disease among the elderly in Denmark: an observational study. BMC Nephrol 2012; 13: 131
15. Hommel K, Rasmussen S, Madsen M et al. The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration. Nephrol Dial Transplant 2010; 25: 947-951
16. Andersen TF, Madsen M, Jorgensen J et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-268 (Pubitemid 29299976)
17. Levey A, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254 (Pubitemid 46768608)
18. Kalayjian R, Franceschini N, Gupta S et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22: 481-487 (Pubitemid 351317289)
19. Lucas GM, Eustace JA, Sozio S et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18: 541-546 (Pubitemid 38365883)
20. Roling J, Schmid H, Fischereder M et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006; 42: 1488-1495
21. Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-456
22. Barrios A, Garca-Benayas T, Gonzlez-Lahoz J et al. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004; 18: 960-963
23. Ryom L, Mocroft A,Worm S et al. Exposure to antiretrovirals (ARVs) and the risk of renal impairment among HIV+ persons with normal baseline renal function: the D:A:D Study. CROI; 12 August 2012: CHIP 2012
24. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342-344 (Pubitemid 36109329)
25. Mocroft A, Kirk O, Reiss P et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-1678
26. Goicoechea M, Liu S, Best B et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-108 (Pubitemid 351263473)
27. Herlitz LC, Mohan S, Stokes MB et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78: 1171-1177
28. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845
29. Behar DM, Kedem E, Rosset S et al. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am J Nephrol 2011; 34: 452-459
30. Nickelsen TN. Data validity and coverage in the Danish National Health Registry. A literature review. Ugeskr Laeger 2001; 164: 33-37 (Pubitemid 34065463)